Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03741764
Other study ID # S61390
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date December 1, 2018
Est. completion date December 2024

Study information

Verified date October 2023
Source Universitaire Ziekenhuizen KU Leuven
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Dupuytren's disease is a progressive fibroproliferative condition of the hand which progresses in 20% of patients into a serious condition. In Flanders, Dupuytren's disease was found to be present in 32% of the population over 50 years. In severe flexion contracture finger deformity due to Dupuytren's disease, functional loss of the finger (often the fourth or fifth digit) is significant. Surgery remains the most efficient treatment for the correction of flexion deformities. Minimal invasive surgery with the creation of firebreaks for the fibrous strands causing this disease, withholds fast recovery. However, recurrence after surgery is not rare with numbers varying from 30 to 70% depending on fibrosis diathesis score of Abe, severity of the deformation and follow-up period. Numerous surgical techniques have been used for Dupuytren disease, ranging from minimally invasive surgery to subtotal preaxial amputation with skin grafting.3 In this study a well-known technique faciectomie will be performed. During this surgery a device will be inserted called VIVOSORB® VIVOSORB® is a flexible bioresorbable polymer film which is designed to separate opposing tissues throughout the critical healing process. It is very flexible facilitating the surgeon to optimally position the sheet during surgery. It is made of 100% synthetic bioresorbable material and can be used in a variety of soft tissue surgery applications. VIVOSORB® provides a barrier function enabling the tissue to regenerate without interconnective attachment. In the past cellulose, a biologic inert implant, was used for augmenting the effect of the surgical firebreaks . Cellulose has been proven to improve outcome. Nowadays, cellulose is not available for use during faciectomie surgery, since medical production has been ceased. VIVOSORB® can be a valid alternative.


Description:

- Trial objectives The objective of this study is to establish if this device is a viable option for treating finger deformity caused by Dupuytren's disease. The main goal is to evaluate the efficacy and performance of this flexible bioresorbable polymer film (VIVOSORB®) Expected outcome is significant correction of the finger extension lack with preserved active finger flexion, without amputation risk or neurovascular damage due to more invasive surgery. - Primary endpoints The device will be considered efficient if the pre-operative lack of finger extension (TPED) compared to the extension at two years post-operative improves by 46°. - Secondary endpoints Patient scores will be evaluated: - Dash score - EQ-5D-3L - VAS pain & satisfaction Amputation is a final endpoint for this study. Secondary a comparison will be made between the population of this study and the population of a previous study in this center³ . In concrete terms this means that the improvement in finger extension will be compared between the VIVOSORB® group, the control³ and the cellulose group³.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject is diagnosed with the disease of Dupuytren - Subject suffers from a severe flexion deformity of the finger(s) - Stage of Dupuytren's disease = 3 as introduced by Tubiana4 - Dupuytren's patients with risk score D of Abe > 4 [5] - Subject is 18 years or older - Subject is willing to sign and date an IRB/EC-approved consent form - Subject receives treatment in UZ Leuven Exclusion Criteria: - Subject is younger than 18 - Subject is not a good candidate for the study based on Investigator opinion

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Vivosorb
Resorbable implant device

Locations

Country Name City State
Belgium UZ Leuven, campus Pellenberg Pellenberg

Sponsors (1)

Lead Sponsor Collaborator
prof. dr. Ilse Degreef

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total Passive Extension Deficit (TPED) TPED of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints of each finger will be measured with an goniometer by an orthopaedic surgeon (the active and passive range of motion flexion and extension). 2 years post-surgery
Secondary DASH score This questionnaire asks the patient about their symptoms as well as their ability to perform certain activities. It's a 30 item questionnaire scored on a Likert scale from 1 (best outcome) to 5 (worst outcome). Maximum total DASH score=100. Higher DASH score indicates worse situation. 2 years post-surgery
Secondary VAS pain & satisfaction On a 10 point scale the patients will score the pain of the hand and the level of satisfaction with the current state of their finger. 0=no pain, 10=worst pain; 0=not satisfied, 10=very satisfied 2 years post-surgery
Secondary EQ-5D-3L Standardised instrument for use as a measure of health outcome 2 years post-surgery
See also
  Status Clinical Trial Phase
Recruiting NCT03155854 - The Effects of Prophylactic Limited Palmar Fasciectomy on Surgical Outcomes and Scarring N/A
Active, not recruiting NCT03192020 - Trial Comparing Treatment Strategies in Dupuytren's Contracture Phase 4
Recruiting NCT05300893 - Effectiveness of Night Splinting After Percutaneous Needle Fasciotomy in Dupuytren's Contracture N/A
Completed NCT02647619 - Dupuytren´s Disease Study. Primary Disease, MCP Joint, Xiapex, PNF Phase 4
Recruiting NCT01184586 - Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010) Phase 2
Recruiting NCT04122313 - Post-contracture Release Radiation for Dupuytren's Disease
Withdrawn NCT01776892 - Collagenase and Needle Aponeurotomy: Single Modality Versus Combination Treatment for Dupuytren's Disease Phase 3
Completed NCT02983162 - Is wGRS Associated With DD Recurrence?
Completed NCT01923103 - Natural Disease Progress of Dupuytren Disease
Enrolling by invitation NCT03982719 - Comparing the Effectiveness of Two Post-fasciectomy Rehabilitation Protocols in Patients With Dupuytren's Disease N/A
Not yet recruiting NCT04907812 - The Role of Tranexamic Acid in Reducing Post Operative Hand Edema After Hand and Wrist Surgery Phase 4
Withdrawn NCT03031080 - BOND Study: the Benefit Of Night Splinting in Dupuytrens' N/A
Completed NCT04874870 - Effectiveness of Splinting After Collagenase Injection Phase 3
Active, not recruiting NCT03407820 - Different Sutures in Hand Surgery N/A
Recruiting NCT03000114 - Collagenase Injection vs Percutaneous Needle Aponeurotomy for Dupuytren's Disease Phase 4
Recruiting NCT05440240 - Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture Phase 4
Completed NCT03331926 - Collagenase is a Common Treatment of MCP and PIP Joint Contractures in Dupuytrens Disease
Completed NCT01876498 - Registry of Patient With M. Dupuytren and Validation of the Brief MHQ N/A
Completed NCT03868449 - Question Prompt List for Common Hand Conditions N/A
Completed NCT03573765 - Epidemiology and Outcomes of Upper Limb Surgery: Analysis of Routine Data